公开(公告)号：US10988540B2

公开(公告)日：2021-04-27

申请号：US16905211

申请日：2020-06-18

Applicant: OSAKA UNIVERSITY

Inventor： Naoki Hosen ,  Haruo Sugiyama ,  Atsushi Kumanogoh ,  Junichi Takagi

IPC: C07K16/00 ,  C07K16/46 ,  C07K16/28 ,  A61K35/17 ,  C12N5/10 ,  C12N15/09 ,  A61K39/00 ,  C07K19/00 ,  A61P35/00 ,  C07K16/30

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

公开(公告)号：US20230357390A1

公开(公告)日：2023-11-09

申请号：US18356489

申请日：2023-07-21

Applicant: OSAKA UNIVERSITY

Inventor： Naoki Hosen ,  Haruo Sugiyama ,  Atsushi Kumanogoh

IPC: C07K16/28 ,  C07K16/30 ,  C07K19/00 ,  A61P35/00 ,  C12N15/62

CPC classification number: C07K16/28 ,  C07K16/3061 ,  C07K16/2896 ,  C07K19/00 ,  A61P35/00 ,  C12N15/62 ,  C07K2317/734 ,  C07K2317/34 ,  C07K2317/33 ,  A61K2039/505

Abstract: Provided is an antibody effective in treating tumors and the like. The antibody recognizes an epitope that contains an N-glycosylation site of human CD98hc and that is exposed by inhibiting N-linked glycosylation.

公开(公告)号：US10654931B2

公开(公告)日：2020-05-19

申请号：US15751574

申请日：2016-08-02

Applicant: OSAKA UNIVERSITY

Inventor： Naoki Hosen ,  Haruo Sugiyama ,  Atsushi Kumanogoh ,  Junichi Takagi

IPC: C07K16/28 ,  A61K39/00 ,  C07K19/00 ,  C12N5/10 ,  C12N5/09 ,  A61K35/17 ,  C12N15/09 ,  A61P35/00 ,  C07K16/30

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.